Specialty Pharmacy

Top news of the day from across the health care landscape.

Investigators find visuals more effective than language when prompting people to self-screen for melanoma.

African Americans can frequently experience barriers in seeking out lifesaving clinical trials for cancer treatments.

The presence of human papillomavirus type 16 antibodies marked an approximately 100-fold increase in risk of throat cancer in white individuals.

Colon cancer may spread to other parts of the body before original tumors are clinically detectable.

Top news of the day from across the health care landscape.

Pembrolizumab (Keytruda, Merck) is indicated for patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least 1 prior line of therapy.

Top news of the day from across the health care landscape.

A new study finds that artificial intelligence diagnoses rare diseases quicker and with more accuracy.

Racial, ethnic, and socioeconomic disparities in cancer survival rates continue to increase for adolescents and young adults.

Study results demonstrate superior efficacy and comparable safety for tildrakizumab versus a placebo in patients with psoriatic arthritis.

Top news of the day from across the health care landscape.

At the Asembia Specialty Pharmacy Summit 2019, a panel of experts educated audience members about chronic inflammatory demyelinating polyneuropathy.

Study findings suggest that triple-negative breast cancer incidence among black women is not generalizable to all women of African descent.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The approval of Amgen’s trastuzumab-anns, the fifth biosimilar to Herceptin, marks the twentieth biosimilar approved by the FDA.

Investigators aim to develop cellular models to mimic the biological processes responsible for the onset of multiple sclerosis.

Slow walking speed associated with higher risk of poor outcomes for older patients with blood cancers.

Top news of the day from across the health care landscape.

Genentech is seeking approval for rituximab (Rituxan) with glucocorticoids for pediatric patients with granulomatosis with polyangiitis and microscopic polyangiitis.

Patients with hemophilia A across all age groups reported stabilization or improvement of quality of life and high treatment satisfaction.

Top news of the day from across the health care landscape.

Pembrolizumab is now indicated for use as a first-line monotherapy treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma.

An unhealthy microbiome caused by chronic antibiotic treatment could result in long-term inflammation within the tissue and tumor environment.

Top news of the day from across the health care landscape.

Polatuzumab vedotin-piiq (Polivy) is a first-of-its-kind anti-CD76b antibody-drug conjugate used in combination with bendamustine plus rituximab (Rituxan) for previously-treated diffuse large B-cell lymphoma.